Abstracts tagged "cyclophosphamide"

Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting
Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Ning Li², Dinesh Khanna³, Michael Roth⁴, Philip J. Clements⁴, Anna-Maria Hoffmann-Vold⁵, Daniel E. Furst¹, Grace Kim⁶, Jonathan Goldin¹ and Robert Elashoff⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Biomathematics, University of California, Los Angeles, Los Angeles, CA, ³University of Michigan, Ann Arbor, MI, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Oslo University Hospital, Oslo, Norway, ⁶Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…
Abstract Number: 1684 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tacrolimus Following Intravenous Cyclophosphamide Pulse Therapy As the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease
Yuki Ichimura, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Tomoaki Higuchi, Yasuhiro Katsumata and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is the disease characterized by organ fibrosis with unknown etiology, and pulmonary involvement is one of major cause of death. However,…
Abstract Number: 2603 • 2017 ACR/ARHP Annual Meeting
Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?
Gabriela Munhoz¹, Maira Lacerda¹, Michelle Lopes¹, Eduardo Ferreira Borba¹, Luciana Seguro² and Eloisa Bonfa³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Low-dose intravenous cyclophosphamide (Euro-lupus) and Mycophenolate mofetil (MMF) are well established in lupus nephritis induction therapy, but there are few studies comparing both treatments.…
Abstract Number: 2624 • 2017 ACR/ARHP Annual Meeting
A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis
Astrid Baumann¹, Angela Pakozdi², Andrea Cove-Smith², Debasish Pyne², Michael Sheaff¹ and Ravindra Rajakariar², ¹Barts Lupus Centre, London, United Kingdom, ²Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Renal biopsies are considered the gold standard in diagnosing lupus nephritis (LN). ALMS (1), the largest randomized trial in LN, reported the non-inferiority of…
Abstract Number: 31 • 2017 ACR/ARHP Annual Meeting
Single Cell Analysis Revealed That the Response to Cyclophosphamide Therapy Is Regulated By B Cells in Systemic Sclerosis-Associated Interstitial Lung Disease
Satoshi Ebata¹, Ayumi Yoshizaki², Takemichi Fukasawa¹, Kouki Nakamura¹, Maiko Hirakawa¹, Takashi Yamashita¹, Shunsuke Miura³, Ryosuke Saigusa¹, Megumi Hirabayashi¹, Asako Yoshizaki¹, Kaname Akamata¹, Yoshihide Asano⁴, Yutaka Kazoe⁵, Kazuma Mawatari⁵, Takehiko Kitamori⁵ and Shinichi Sato⁶, ¹Dermatology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁴Applied Chemistry, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁵Applied Chemistry, University of Tokyo, Graduate School of Engineering, Tokyo, Japan, ⁶Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of several organs. SSc-associated interstitial lung disease (ILD) is a frequent and severe complication…
Abstract Number: 6L • 2016 ACR/ARHP Annual Meeting
Myeloablative Autologous Transplantation of CD34+ -Selected Hematopoietic Stem Cells (HSCT) Vs Monthly Intravenous Cyclophosphamide (CYC) for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial
Keith Sullivan¹, Lynette Keyes-Elstein², Peter McSweeney³, Ashley Pinckney², Beverly Welch⁴, Maureen D Mayes⁵, Richard Nash³, Leslie J. Crofford⁶, Sharon Castina², Linda Griffith⁷, Ellen Goldmuntz⁸ and Daniel E. Furst⁹, ¹Duke University, Durham, NC, ²Rho, Inc, Chapel Hill, NC, ³Colorado Blood Cancer Institute, Denver, CO, ⁴6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁵Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ⁶Medicine, Vanderbilt University Medical Center, Nasville, TN, ⁷NIAID, NIH, Bethesda, MD, ⁸NIAID, National Institutes of Health, Bethesda, MD, ⁹David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Therapeutic options for diffuse cutaneous systemic sclerosis (dcSSc) are limited. The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial was a multicenter study designed to…
Abstract Number: 776 • 2016 ACR/ARHP Annual Meeting
Eurolupus and Low Steroid Regimen in Proliferative Lupus Nephritis: Retrospective Evaluation of 38 Patients in the Black Population of Martinique
Charles Cartou¹, Katlyne Polomat², Florence MOINET², Serge ARFI³, Lauren Brunier-Agot⁴, Marie Blattery⁵, Aymeric Couturier⁶, Georges JEAN BAPTISTE⁷, Michel De Bandt⁸ and Christophe Deligny⁹, ¹nephrology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, ²Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort de France, Martinique, ³University Hospital, CHU Fort de France, Fort de France, Martinique, ⁴Internal medicine and rheumatology, Zobda Quitman Hospital, Fort de France, Martinique, ⁵rheumatology, Pierre Zobda Quitman hospital, Fort de France, Martinique, ⁶nephrology, Pierre Zobda Quitman hospital, Fort de France, Martinique, ⁷RHEUMATOLOGY, CHU MARTINIQUE, FWI, Fort-de-France, Martinique, ⁸CHU Fort de France, Fort de France, France, ⁹Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique
Background/Purpose: There is no data on the efficacy of the EUROLUPUS regimen associated with initial low steroids daily dose in African descent patients with proliferative…
Abstract Number: 1394 • 2016 ACR/ARHP Annual Meeting
A Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis
Jennifer C. Cooper¹, B. Anne Eberhard², Marilynn Punaro³, Stacy P. Ardoin⁴, Hermine I. Brunner⁵, Joyce Hsu⁶, Linda Wagner-Weiner⁷, Kelly Rouster-Stevens⁸, Laura E. Schanberg⁹, Marisa Klein-Gitelman¹⁰, Emily von Scheven¹¹ and CARRA Registry Investigators, ¹Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Cohen Children's Medical Center of New York, New Hyde Park, NY, ³Texas Scottish Rite Hospital for Children, Dallas, TX, ⁴Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ⁵Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁷Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁸Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁹Pediatrics, Duke Medical Center, Durham, NC, ¹⁰Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ¹¹Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA
Background/Purpose: Childhood-onset systemic lupus erythematous (cSLE) patients are at higher risk for renal disease than those with adult-onset disease. Mycophenolate mofetil (MMF) and intravenous…
Abstract Number: 1872 • 2016 ACR/ARHP Annual Meeting
The Effect of Cyclophosphamide on Pulmonary Function and Dependence on Disease Activity of Interstitial Lung Disease Associated with Systemic Sclerosis
WMT van den Hombergh¹, E. Teesselink¹, HKA Knaapen-Hans¹, FHJ van den Hoogen², S.O. Simons³, J. Fransen⁴ and MC Vonk¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboudumc, Nijmegen, Netherlands, ³Respiratory Medicine, Radboud University Medical Centre, Nijmegen, Netherlands, ⁴Department of Rheumatolgy, Radboudumc Nijmegen, Nijmegen, Netherlands
THE EFFECT OF CYCLOPHOSPHAMIDE ON PULMONARY FUNCTION AND DEPENDENCE ON DISEASE ACTIVITY OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS W. M. T. Van Den…
Abstract Number: 1953 • 2016 ACR/ARHP Annual Meeting
Management and Outcomes of ANCA-Associated Vasculitis in Unselected Cases within a Large Health Region of England
Fiona Pearce¹, Catherine McGrath², Ravinder Sandhu³, Jon Packham⁴, Karen Obrenovich⁵, Richard A. Watts⁶, Peter Lanyon⁷ and for the East Midlands, West Midlands and East of England regional audit groups, ¹Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom, ²Department of Rheumatology, The Dudley Group NHS Foundation Trust, Dudley, United Kingdom, ³The Dudley Group NHS Foundation Trust, Dudley, Great Britain, ⁴University of Keele, Keele, United Kingdom, ⁵The Dudley Group NHS Foundation Trust, Dudley, United Kingdom, ⁶Rheumatology Department, Ipswich Hospital, Ipswich, Great Britain, ⁷Department of Rheumatology, Nottingham University Hospitals NHS trust, Nottingham, United Kingdom
Background/Purpose: Most data on management and outcomes of ANCA-associated vasculitis (AAV) come from highly selected populations in tertiary referral centres, or clinical trials. These results…
Abstract Number: 2326 • 2016 ACR/ARHP Annual Meeting
Intravenous Cyclophosphamide Followed By Oral Immunosuppressive Treatment Versus Rituximab in Inflammatory Myopathy-Related Interstitial Lung Disease
Vincent Langlois¹, Kuberaka Mariampillai², Nicolas Champtiaux³, Marie-Laure Chabi⁴, Yurdagul Uzunhan⁵, Eric Hachulla⁶, Olivier Benveniste⁷ and Baptiste Hervier³, ¹Internal Medicine, University Hospital, Rouen, France, ²Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ³Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Radiology department, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁵Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁶Internal Medicine, Lille University Hospital, Lille, France, ⁷Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Interstitial lung disease (ILD) associated with inflammatory myopathy (IM) has a poor prognosis and requires specific treatments. Intravenous Cyclophosphamide (CYC) is one of the…
Abstract Number: 2815 • 2016 ACR/ARHP Annual Meeting
Comparison of Lupus Nephritis Induction Therapy with Cyclophosphamide High Dose Versus Low Dose
Juliana Valim¹, Verônica Lima², Fernanda Guimarães³, Fernanda Chaer⁴ and Branca Souza⁵, ¹Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ²Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁵Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil
Background/Purpose: To Compare the induction therapy of lupus nephritis with cyclophosphamide (CYC) high dose or low dose and identify possible predictors of disease remission. Methods:…
Abstract Number: 2971 • 2016 ACR/ARHP Annual Meeting
Characteristics and Management of IgA Vasculitis (Henoch-Schönlein purpura) in Adults: Data from the 260 Patients Included in the Igavas Survey
Alexandra Audemard-Verger¹, Evangeline Pillebout², Agnès Dechartres³, Johan Chanal⁴, Zahir Amoura⁵, Noemie Le Gouellec⁶, Patrice Cacoub⁷, Noémie Jourde-Chiche⁸, Geoffroy Urbanski⁹, Jean-Francois Augusto⁹, Guillaume Moulis¹⁰, Loic Raffray¹¹, Alban Deroux¹², Aurélie Hummel¹³, Bertrand Lioger¹⁴, Melanie Catroux¹⁵, Stanislas Faguer¹⁶, Julie Goutte¹⁷, Nihal Martis¹⁸, Francois Maurier¹⁹, Etienne Riviere²⁰, Sébastien Sanges²¹, Aurélie Baldolli²², Nathalie Costedoat-Chalumeau²³, Melanie Roriz²⁴, Xavier Puéchal²⁵, Marc Andre²⁶, Christian Lavigne²⁷, Boris Bienvenu²⁸, Arsène Mékinian²⁹, Elie Zagdoun³⁰, Charlotte Girard³¹, Alice Berezne³², Loïc Guillevin²⁵, Eric Thervet³³ and Benjamin Terrier³⁴, ¹Internal Medicine, Caen, France, ²Nephrology, Saint Louis, Paris, France, ³Epidemiology, Hotel Dieu, Paris, France, ⁴Dermatology, Cochin Hospital, Paris, France, ⁵Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁶Internal Medicine, Lille, France, ⁷Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et d’Immunologie clinique, DHU i2B, Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ⁸Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ⁹Internal Medicine, CHU, Angers, France, ¹⁰CHU Purpan, Toulouse, France, ¹¹Internal Medicine, CHU de Bordeaux, Bordeaux, France, ¹²Internal Medicine, CHU Grenoble, Grenoble, France, ¹³Necker, paris, France, ¹⁴GICC UMR 7292, University François Rabelais, Tours, France, ¹⁵Internal Medicine, Cochin Hospital, Paris, France, ¹⁶Nephrology, CHU, Toulouse, France, ¹⁷Internal Medicine, CHU, Paris, France, ¹⁸Internal Medicine, CHU, Nice, France, ¹⁹Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ²⁰Internal Medicine, CHU, Bordeaux, France, ²¹Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ²²Internal Medicine, CHU, Caen, France, ²³Internal Medicine, Cochin University Hospital, Paris, France, ²⁴internal Medicine, Lariboisière, Paris, France, ²⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²⁶Internal Medicine CHU G Montpied, Internal Medicine, Clermont Ferrand, France, ²⁷CHU Angers, department of Internal Medicine, Angers, France, ²⁸Caen University Hospital, Caen, France, ²⁹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ³⁰Internal Medicine, CH, Saint-Lo, France, ³¹Internal Medicine, CHU, Lyon, France, ³²Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ³³Nephrology, Hopital Européen Georges Pompidou, APHP, PARIS, France, ³⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: We analyzed data from 260 patients with IgAV included in a French multicenter retrospective IGAVAS survey. Results: Mean age at diagnosis was 50.1±18 years,…
Abstract Number: 3203 • 2016 ACR/ARHP Annual Meeting
Analysis of Efficacy and Safety of Cyclophosphamide in Juvenile Dermatomyositis Using a Large National UK Cohort
Claire Deakin¹, Raquel Campanilho-Marques², Stefania Simou³, Elena Moraitis⁴, Eleanor Pullenayegum^5,6, Lucy R Wedderburn^4,7,8, Clarissa Pilkington⁹ and Juvenile Dermatomyositis Research Group (JDRG), ¹Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, Portugal, ³Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁴Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁵Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ⁶Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁷Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁹Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Cyclophosphamide (CYC) has been used as a second-line agent in the treatment of severe or refractory JDM. The published literature on the efficacy of…
Abstract Number: 3248 • 2016 ACR/ARHP Annual Meeting
Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post-Hoc Analyses from the Scleroderma Lung Study I and II
Rajaie Namas^1,2, Donald P. Tashkin³, Holly Wilhalme⁴, Daniel E. Furst⁵, Chi-hong Tseng⁶, Michael Roth⁶, Suzanne Kafaja⁷, Elizabeth R. Volkmann⁴, Philip J. Clements⁶ and Dinesh Khanna⁸, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ³David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵UCLA, Los Angeles, CA, ⁶Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸University of Michigan, Ann Arbor, MI
Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II. Background/Purpose: Assess the efficacy of…